Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients
The three platforms demonstrated high correlation and comparable performance in sNfL quantification. About 3 % of samples showed strong deviations, highlighting the need for vigilance and further harmonization. Age-adjusted Z scores may enhance clinical and research utility.
Authors
- Antje Torge
- Frank Leypoldt (ORCID: https://orcid.org/0000-0002-8972-515X)
- Klaus‐Peter Wandinger (ORCID: https://orcid.org/0000-0002-5483-4276)
- Malte Ziemann (ORCID: https://orcid.org/0000-0003-0919-0237)
- Eline Willemse (ORCID: https://orcid.org/0009-0009-8093-8755)
- Jens Kühle (ORCID: https://orcid.org/0000-0002-6963-8892)
- Robert Markewitz (ORCID: https://orcid.org/0000-0003-1676-1085)
- Aleksandra Maleska
- Sven Ole Schuster
- Michael Khalil (ORCID: https://orcid.org/0000-0002-5350-3328)
- Justina Dargvainiene (ORCID: https://orcid.org/0009-0002-4114-3748)
- Pascal Benkert (ORCID: https://orcid.org/0000-0001-6525-8174)
- Cansu Tafrali (ORCID: https://orcid.org/0009-0003-2910-3791)
- Ralf Junker
- Maria Martinez-Serrat
Institutions
- Medical University of Graz (AT)
- University Hospital of Basel (CH)
- University Hospital Schleswig-Holstein (DE)
- Department of Biomedicine Basel (CH)
- University of Lübeck (DE)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1515/cclm-2025-1476
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- Universität Basel
- International Progressive MS Alliance
- E-Rare
- Argenx
- National Research Foundation
- Bundesministerium für Bildung und Forschung
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz
- Neuraxpharm
- Grifols